LC-Fatty Acid Oxidation Disorders: Recent Updates on the REN001 Study

Event Date:

August 18, 2022

Event Time:

12:00 am

Print Friendly, PDF & Email

There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.

Please join us for an update on the Reneo LC-FAOD study. Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about this clinical study and will answer your questions.




Share This Events: